Atlas Venture Fund XII, L.P. → Aerovate Therapeutics, Inc. JBIO

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

1 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-07-15

DTC 7.16

7,528,320 shares short · -7.6% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-06-25	Eisner Mark	director	Award	47,675	$21.81	$1.04M

Other 13D/G Filings on Aerovate Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-06-09	SCHEDULE 13D/A	Fairmount Funds Management LLC	19.99%	14,069,494	view →
2025-04-30	SCHEDULE	Atlas Venture Fund XII, L.P.	20.00%	51,406	view →
2025-04-30	SCHEDULE	RA CAPITAL MANAGEMENT, L.P.	4.10%	1,324,954	view →
2024-06-20	SC	RA CAPITAL MANAGEMENT, L.P.	—	—	view →
2024-02-20	SC	Sofinnova Venture Partners X, L.P.	—	—	view →

Other Filings by Atlas Venture Fund XII, L.P.

Filed	Form	Issuer	Stake	Shares
2025-04-30	SCHEDULE	Aerovate Therapeutics, Inc. JBIO	20.00%	51,406	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →